Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new drugs and drug regimens. A major goal is to identify new agents that can be combined together in novel regimens or combined with existing drugs to shorten the duration of TB therapy.
A newer interest is to develop improved animal models of non-tuberculous mycobacterial infection to enable a similar approach to drug and regimen development for these difficult-to-treat infections.
Technology Expertise Keywords
Tuberculosis; Drug Development; Antibiotic Resistance; Pharmacodynamics; Infectious Disease; Infectious Diseases
View all on PubMed
Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, Nuermberger E. Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541OC. Online ahead of print. PMID: 34939891
Rifat D, Chen L, Kreiswirth BN, Nuermberger EL. Genome-Wide Essentiality Analysis of Mycobacterium abscessus by Saturated Transposon Mutagenesis and Deep Sequencing. mBio. 2021 Jun 29;12(3):e0104921. doi: 10.1128/mBio.01049-21. Epub 2021 Jun 15. PMID: 34126767
Almeida DV, Converse PJ, Omansen TF, Tyagi S, Tasneen R, Kim J, Nuermberger EL. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrob Agents Chemother. 2020;64(6):e00259-20
Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015; 60:270-7
Rosenthal IM, Zhang M, Williams K, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model, PLoS Medicine, 2007;4:e344